Introduction
Prolactin (PRL) is a member of a group of polypeptide hormones that includes growth hormone and placental lactogen. Synthesized primarily by lactotropes in the anterior pituitary, PRL is critically involved in normal mammary gland development (Nagasawa et al., 1985; Clevenger et al., 1995; Vonderhaar, 1998; Blackwell and Hammond, 1999) . In addition to its role as an endocrine hormone, human PRL (hPRL) is also produced by the breast epithelium as an autocrine/paracrine growth factor, and as such functions as a cytokine (Clevenger et al., 1995 (Clevenger et al., , 2003 Ginsburg and Vonderhaar, 1995; BenJonathan et al., 2002) . The finding of the extrapituitary role of hPRL links hPRL to human breast cancer (Vonderhaar, 1999) and includes evidence such as (a) the detection of biologically active hPRL in human breast cancer cells and tumors (Clevenger et al., 1995; Ginsburg and Vonderhaar, 1995; Bhatavdekar et al., 2000) ; (b) the finding of increased levels of hPRL receptor (PRLR) levels in human breast cancer cells over normal breast epithelial cells (Binart et al., 2000) ; (c) the finding that transgenic mice overexpressing hPRL have a higher breast cancer rate (Wennbo et al., 1997) ; (d) the recent observation that hPRL stimulates angiogenesis (Corbacho et al., 2002) ; and (e) the finding that the hPRL antagonist hPRL-G129R slows the growth rate of human breast cancer cells in vitro and in xenografts of nude mice (Chen et al., 1999 . Taken together, these findings lend support to the mitogenic importance of hPRL in breast cancer development and progression, and suggest that its antagonist could have a potential in treating human breast cancer.
The elimination of tumors by the induction of apoptosis, or programmed cell death, is the most common mechanism of cancer therapeutics (Zhang et al., 2000) . One of the first regulators of apoptosis to be identified was Bcl-2, which is now known to be an antiapoptotic member of one of three subfamilies of related proteins, all of which share at least one Bcl-2 homology (BH) domain (Adams and Cory, 1998; Cory and Adams, 2002) . It is encoded by bcl-2, a human proto-oncogene (Korsmeyer, 1999) , and suppresses apoptosis by blocking the release of cytochrome c (a heme protein required for cellular respiration) from the mitochondria, thus preventing the activation of caspases, a group of cysteine proteases that carry out the process of cell death (Yin et al., 1994; Kumar et al., 2000) . Bcl-2 remains associated with the outer mitochondrial membrane, maintaining its integrity. In response to damage or stress signals, Bax monomers are translocated from the cytosol, oligomerize, and induce permeabilization of the mitochondrial mem-brane, leading to the release of proapoptotic proteins and activation of several key caspases, most notably caspase 9. This permeabilization is thought to function as the 'apoptotic checkpoint' (Debatin et al., 2002) . In human mammary tissue, Bcl-2 and Bax, its proapoptotic homolog, are constitutively expressed to tightly regulate apoptosis during normal developmental processes (Yin et al., 1994; Binder et al., 1996; Adams and Cory, 1998; Kumar et al., 2000) . Breast malignancy requires the upregulation of bcl-2 gene expression, ultimately resulting in the inhibition of apoptosis (Green and Beere, 1999; Krajewski et al., 1999) . Studies using Nb2 cells, a rat lymphoma hPRL-dependent cell line, have demonstrated bcl-2 upregulation and bax downregulation following treatment with hPRL (Krumenacker et al., 1998; Schorr et al., 1999) .
In our previous studies, we reported that hPRL and hPRL-G129R regulate Bcl-2 gene expression in multiple human breast cancer cells . In this work, we extended that study to include the measurement of bax gene expression and determination of the bax/bcl-2 mRNA ratios in 11 human breast cancer cell lines, following treatment with the hPRL antagonist hPRL-G129R. A time-course study of bax and bcl-2 levels in T-47D cells following hPRL and antagonist treatments was first conducted. We also quantified bax and bcl-2 expression in hPRL or hPRL-G129R transgenic mice of three age groups. We confirmed our findings linking increased bax expression to hPRL-G129R exposure at the protein level by Western blot, and by detection of cytochrome c release.
Results
Bax mRNA levels and bax/bcl-2 ratios are increased in response to hPRL-G129R treatment in a majority of human breast cancer cell lines examined
To determine the time course of the response of T-47D cells to treatments, cells were treated with either 500 ng/ ml of hPRL or hPRL-G129R. The mRNA levels of bax and bcl-2 levels were measured using real-time reverse transcription-polymerase chain reaction (RT-PCR) at five time points: 2, 6, 24, 48 and 72 h. Levels of bax and bcl-2 were normalized to levels in the untreated samples, and results are presented as the ratio of treated to untreated values for each time point. The maximum response of bax to hPRL-G129R treatment was observed after 48 h of treatment ( Figure 1a) . bax levels at 24, 48 and 72 h were all statistically different from those of the untreated cells. Figure 1b , representing the time course of bcl-2 response to hPRL and hPRL-G129R treatments, indicated that the upregulation of bcl-2 by hPRL and downregulation by hPRL-G129R were most pronounced by 48 h. The reduction of bcl-2 in response to hPRL-G129R treatment was more rapid than the increase in bcl-2 levels in response to hPRL treatment. When the mean bax/bcl-2 ratios for the hPRL and hPRL-G129R treatments were compared (Figure 1c) , it is apparent that hPRL-G129R increased, whereas hPRL decreased the ratio of bax/bcl-2. From these results, the 48 h treatment was chosen as the time point for subsequent real-time RT-PCR analyses in multiple cell lines.
As summarized in Figure 2 and Table 1 , bax levels were significantly upregulated in response to hPRL-G129R treatment in five of the 11 cell lines (Figure 2a) , with smaller increases in three cell lines. In a previous study , we measured bcl-2 levels in response to hPRL and hPRL-G129R treatments in these Time-course study of Bax and Bcl-2 mRNA levels in response to hPRL or hPRL-G129R treatment in T-47D cells, as measured by real-time RT-PCR at five different time points. Cells were treated with 500 ng/ml of hPRL or hPRL-G129R in RPMI media containing 2% CSS, and total RNA was extracted after 2, 6, 24, 48 and 72 h. Panel a, Bax mRNA levels; panel b, Bcl-2 mRNA levels; and panel c, ratios of Bax/Bcl-2 mRNA levels calculated from the mean value of each data point as fold change from the untreated controls same cell lines (Figure 2b ). In the present study, we found that increases in bax levels in response to hPRL-G129R treatment corresponded to levels of increase in bcl-2 in response to hPRL treatment. Presented as the mean ratio of bax/bcl-2 (Figure 2c ), the bax/bcl-2 ratios for hPRL-G129R treatment indicated a major increase in seven of the 11 cell lines. In an earlier study (Peirce and Chen, 2001 ), we reported PRL receptor (PRLR) levels in these same cell lines. Here, the cell lines with the higher levels of PRLR (T-47D, BT-134, MDA-MB-453, MCF-7, BT-474) were the most responsive to both hPRL and hPRL-G129R treatments, with the two cell lines having the highest PRLR levels showing the largest bax/bcl-2 ratios (Figure 2c ).
Bax and Bcl-2 mRNA levels in mammary gland tissue homogenates from MT-hPRL and MT-hPRL-G129R transgenic mice
The transgenes are regulated by the metallothionine promoter (MT) and are, therefore, constitutively expressed in a majority of tissues including the mammary gland. The transgenes are continually expressed throughout the lifetime of the animals studied (data not shown). The levels of hPRL and hPRL-G129R expression in the serum of these animals ranged between 5 and 10 ng/ml, as measured by a 125 I immunoradiometric serum assay, Coat-A-Count PRL IRMA (Diagnostic Products Corporation, LA, CA, USA). We did not observe any significant alteration in the ability of the PRL or G129R transgenic mice to reproduce, since both males and females of these mice are fertile. This may be due to the fact that the transgene expression levels were relatively low. Total RNA isolated from the mammary glands of hPRL or hPRL-G129R transgenic mice (4-7 mice per group; 3, 6-7 and 9-12 months of age) was analysed for levels of bax and bcl-2. Nontransgenic littermates were used as the controls. Data were presented as the ratio of gene expression levels of the transgenic mice to those of the nontransgenic littermates. Thus, a ratio of 1 indicates that there is no difference in gene expression between the transgenic and its nontransgenic littermate. Within the 3-and 6-month age groups, levels of Bax mRNA were not statistically different between hPRL and hPRL-G129R transgenic mice (Figures 3a) . However, by 9 months, levels of bax were significantly upregulated in hPRL-G129R transgenics (Po0.001). Levels of Bcl-2 mRNA showed a response at an earlier age. By 6 months, levels of Bcl-2 mRNA were highly upregulated in the hPRL group of transgenics (Po0.01). However, this difference diminished with increasing age of the mice; within the 9-12-month age groups, bcl-2 levels were not significantly different between hPRL and hPRL-G129R transgenic mice. bax/bcl-2 ratios were also compared for each age group (Figure 3b) . At 3 months, there was little difference between the hPRL and hPRL-G129R transgenic mice. However, by 6-7 months, the bax/bcl-2 ratio was 0.214 for the hPRL transgenics (largely due to upregulation of bcl-2) as compared to their nontransgenic littermates, and 2.43 for the hPRL-G129R transgenics (largely due to upregulation of bax), a 11-fold difference in bax/bcl-2 ratios between hPRL and hPRL-G129R transgenic mice. By 9-12 months, the difference between bax/bcl-2 ratios had diminished somewhat, to a five-fold increase in the bax/bcl-2 ratio of the hPRL-G129R transgenics over the hPRL transgenics.
Bax, Bcl-2 and cytochrome c protein levels in the mammary gland tissue of MT-hPRL and MT-hPRL-G129R transgenic mice all the three age groups were analysed for levels of Bax, Bcl-2 and cytochrome c proteins (Figure 4a-c) . At 3 months, the levels of Bax and Bcl-2 were similar between the two groups of transgenics, although the hPRL-G129R transgenics were already expressing slightly more Bax at the protein level ( Figure 4a ). By 6 months, the hPRL-G129R transgenics were expressing considerably more Bax protein than the corresponding hPRL transgenics (Figure 4b ). At 9 months, both transgenic groups were producing high levels of Bax ( Figure 4c ). When these expression levels were quantified from densitometric scans and the Bax/Bcl-2 ratios were calculated using the levels of the nontransgenic littermates as the baseline (Figure 4 inset), statistically significant differences were seen between the 6-month groups, with the hPRL-G129R transgenics expressing proportionally much higher levels of Bax. All samples were normalized to levels of a-tubulin, as quantified by densitometric scanning. Age-matched changes in Bax and Bcl-2 levels between the two groups of transgenics were paralleled by changes in cytochrome c (Figure 4) . At 3 months, there is a low level of cytochrome c expression in the hPRL-G129R group, not seen in the hPRL transgenics or the litter-matched nontransgenic animals. At 6 months, this level of cytochrome c expression had markedly increased in the hPRL-G129R transgenic animals. However, by 9 months, both the hPRL-G129R and the hPRL transgenic animals expressed high levels of cytochrome c, relative to their nontransgenic littermates. Similar results were found using human breast cancer cells (T-47D and MB-453) following treatment with hPRL-G129R. Cytosolic cytochrome c levels showed a dose-and timedependent response to hPRL-G129R treatment (data not shown).
Discussion
In our previous studies, it was shown that the PRL receptor antagonist hPRL-G129R is able to inhibit human breast cancer cell proliferation through the induction of apoptosis (Chen et al., 1999) . It was further established that hPRL-G129R-induced apoptosis is mediated through the inhibition of the antiapoptotic effects of hPRL via the downregulation of Bcl-2 gene expression . In this study, evidence from breast cancer cells, as well as from transgenic mice, Figure 3 Bax and Bcl-2 mRNA levels in mammary gland tissues of hPRL and hPRL-G129R transgenic mice of three age groups. Bax and Bcl-2 expression levels were quantified using real-time RT-PCR, and were normalized to 18s rRNA levels. Panel a, Bax (left) and bcl-2 (right) mRNA levels in hPRL and hPRL-G129R transgenics, relative to nontransgenic littermates; and panel b, comparison of fold change of bax/bcl-2 ratios in hPRL and hPRL-G129R transgenics adjusted to levels of nontransgenic littermates Upregulation of Bax expression by hPRL-G129R SK Peirce and WY Chen is presented, which suggests that both Bax and Bcl-2 expression are regulated by hPRL-G129R.
The time course of Bax mRNA increase in response to hPRL-G129R treatment matched the response of bcl-2 following PRL treatment in T-47D cells (Figure 1) . It is widely accepted that the overall Bax/Bcl-2 status ultimately decides the apoptotic fate of the cell (Debatin et al., 2002) . The data presented in this study suggest that the balance is tipped in favor of apoptosis, following hPRL-G129R treatment in seven of these 11 cell lines (Figure 2c ). In the examination of the entire panel of human breast cancer cell lines, it was found that the cell lines with highest response levels of bcl-2 to hPRL treatment (MCF-7, T-47D and MDA-MB-134) also had the highest levels of bax in response to hPRL-G129R treatment (Figure 2) . The cell lines that demonstrated decreased bcl-2 responses to hPRL treatment (MDA-MB-436, MDA-MB-468, MDA-MB-231, BT-483) were also less responsive to treatment with hPRL-G129R. Not surprisingly, these cell lines also have lower PRLR levels (Peirce and , suggesting that, in these cell lines, PRL plays a less significant role in the regulation of bax and bcl-2 expression.
From our previous study, it is apparent that both the death receptor (Bcl-2-independent) pathway and the mitochondrial membrane permeabilization (MMP) pathway are represented in the microarray panel of four cell lines, and presumably in the larger panel of 11 breast cancer cell lines; the presence of these pathways is likely mirrored by the Bax/Bcl-2 and cytochrome c responses to hPRL and hPRL-G129R treatments. It is plausible that the proapoptotic PRL antagonist acts by slowing more aggressive growth by direct blockage of proliferative cascades, allowing the initiation of upregulation of possible apoptotic pathways; in particular, the c-jun N-terminal kinase (JNK) kinases have been suggested as possible candidates (Debatin et al., 2002) . In addition, the post-translational form of the hPRL protein may determine the signal transduction pathway(s) induced in each situation (MAPK-Ras/Raf vs Jak2/Stat), and hence the levels of Bax or Bcl-2. For example, PRL undergoes a number of post-translational modifications, most importantly phosphorylation. A molecular mimic of phosphorylated PRL has been found to be involved in differentiation, rather than proliferation, whereas the unphosphorylated form is primarily involved in proliferative processes (Kuo et al., 2002) .
From the in vivo studies, it is apparent that Bax, Bcl-2 and cytochrome c levels were under the dual influences of developmental and age-related changes, as well as the transgenes hPRL or hPRL-G129R. The real time RT-PCR data indicated a major increase in bcl-2 levels in the hPRL group at 6 months and a major increase in bax levels in the hPRL-G129R group at 9 months relative to the nontransgenic littermates (Figure 3) . However, the largest bax/bcl-2 gene expression ratio is seen in the hPRL-G129R transgenics at 6 months ( Figure 3b) , and this is reflected in the release of cytochrome c; thus, gene expression is linked to an apoptotic outcome in this system. At the protein level, there was a major increase in Bax in the hPRL-G129R group at 6 months, accompanied by cytochrome c release (Figure 4b ). There were major increases in Bax and cytochrome c release in the hPRL group of transgenics at 9 months (Figure 4c) . At 6 months, overexpression of hPRL-G129R led to apoptotic processes, while overexpression of hPRL was linked to the upregulation of Bcl-2 mRNA. However, by 9 months, it is plausible that prolonged exposure to elevated levels of systemic hPRL led to a recapitulation of events seen in early involution. By accelerating events normally seen in PRL-induced proliferation (Brockman , 1997) . There was an apparent discrepancy in the concentrations of G129R needed to induce a significant response between our in vitro and in vivo models. We reasoned that, in the transgenic mice, the mammary gland is continually exposed to G129R and PRL, and that G129R is acting in an autocrine/paracrine manner; the low levels of PRL and G129R are sufficient to induce a significant response as compared to that of nontransgenic counterparts. However, the breast cancer cell lines used in this study were not only transformed and malignant, but have also been reported (T-47D cells) to produce PRL. Therefore, a much higher concentration of G129R was needed to induce a similar response. In summary, the data presented here suggest that Bax is upregulated in response to hPRL-G129R stimulation both in vitro and in vivo; the expression of Bax is closely linked to cytochrome c release. However, the full extent of the Bax/Bcl-2 response may be modulated by other factors such as PRLR levels. The transgenic animal models that we have developed will allow us to evaluate pathways such as Jak2/Stat and Ras-MAPK in the context of such receptor levels, which are involved in the regulation of Bax and Bcl-2. Thus, apoptosis induced by hPRL-G129R in these breast cancer model systems is driven, at least in part, by the simultaneous downregulation of Bcl-2 and the upregulation of Bax at both the mRNA and protein levels, regulation that leads to the ultimate release of cytochrome c. In total, these data support the growing body of evidence of the potential importance of this PRL receptor antagonist for the treatment of breast cancer. were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained as previously described .
Materials and methods

Cell lines, growth conditions and treatments of cells for real-time RT-PCR
Before treatment, the 11 breast cancer cell lines were transferred to their respective medium minus phenol red supplemented with 10% charcoal stripped serum (CSS) (Hyclone Laboratories, Logan, UT, USA) and grown for 1-2 days, reaching an approximate 75% level of confluency. Approximately 0.5À1 Â 10 7 cells from each group were treated with 500 ng/ml of hPRL-G129R in medium containing 2% CSS. The untreated control cells were cultured in cell-specific medium supplemented with 2% CSS. All cells were treated for 48 h and harvested for total RNA extraction using the RNAqueous (Ambion, Austin, TX) RNA isolation kit, following the recommended protocol.
Transgenic mice and procedures
MT-regulated hPRL and hPRL-G129R cDNA were used to create hPRL and hPRL-G129R transgenic founder mice from the B6C3F1 strain (Jackson Labs, Bar Harbor, ME, USA) by microinjection into single-cell embryos. Transgenic mice were confirmed by PCR for the presence of hPRL and hPRL-G129R cDNAs (data not shown). The serum expression levels of hPRL and hPRL-G129R from the transgenic mice ranged from 5 to 10 ng/ml, as measured by a 125 I immunoradiometric serum assay, Coat-A-Count PRL IRMA (Diagnostic Products Corporation, LA, CA, USA). The human PRL IRMA assay is equally sensitive to hPRL and G129R (data not shown). To ensure the specificity of the measurement, nontransgenic mouse serum was used to generate a negative baseline. For the evaluation of Bax and Bcl-2 mRNA and protein expression, mice were grouped into three age categories: 3 months, 6-7 months and 9-12 months. Each group contained 4-6 hPRL or hPRL-G129R transgenic mice, and 2-4 white, nontransgenic littermates.
Isolation of total RNA from mouse mammary gland tissues
Fresh mammary gland tissue was flash-frozen on dry ice or in liquid N 2 , and stored at À801C until use. For RNA isolation, an approximate 50 mg portion of frozen tissue was added to 1 ml RNA lysis/binding buffer (Ambion, Austin, TX, USA). The tissue was homogenized using a Polytron PT 1200 B, and total RNA was extracted using the RNAqueous (Ambion) RNA isolation kit, following the recommended protocol. RNA was quantified by UV spectrophotometry.
One-step real-time RT-PCR
A one-step real-time RT-PCR technique was used to determine the relative expression levels of bax mRNA, using the ABI Perkin-Elmer Prism 7700 Sequence Detection System (Perkin-Elmer Biosystems, Foster City, CA, USA). The reaction mix included a 200 nm final concentration of both forward (derived from exon 3 : 5 0 -CCGCCGTGGACACA-GAC-3 0 ) and reverse (derived from exon 5 : 5 0 -CAGAAAA-CATGTCAGCTGCCA-3 0 ) bax-specific primers, and a 100 nm final concentration of the bax-specific FAM-labeled probe (5 0 -6FAM-CCCCCCGAGAGGTCTTTTTCCGAC-TAMRA-3 0 ). For detection of bcl-2 mRNA, the reaction mix included a predeveloped TaqMan assay mixture containing both forward and reverse bcl-2-specific primers, and a 100 mM final concentration of the bcl-2-specific probe labeled with FAM reporter fluorescent dye (Perkin-Elmer). A one-step reaction mixture provided in the TaqMan s Gold RT-PCR Kit (PerkinElmer) was used for all amplifications (5.5 mM MgCl 2 , 50 mM KCl, 0.01 mM EDTA, 10 mM Tris-HCl pH 8.3, 300 mM deoxyATP, 300 mM deoxyCTP, 300 mM deoxyGTP, 600 mM deoxyUTP, 0.025 U/ml AmpliTaq Gold DNA polymerase, 0.25 U/ml MultiScribe Reverse Transcriptase, 0.4 U/ml RNase inhibitor). Cycle parameters for the one-step RT-PCR included a reverse-transcription step at 481C for 30 min, followed by 40 cycles of 951C denaturation and 601C annealing/extension. In all, 400-1500 ng of total RNA was used per reaction. The housekeeping gene b-actin (Applied Biosystems P/N 401846) was used for internal normalization for RNA isolated from cell cultures; for expression from mammary gland tissue-derived RNA, 18s rRNA (Applied Biosystems PDAR-4310) was used for internal normalization. Each reaction was carried out in duplicate for each PCR run, and each run was repeated two to five times. Data are expressed as the means7s.e.
Extraction of protein from mouse mammary gland tissue
Fresh mammary gland tissue was flash-frozen on dry ice or in liquid N 2 , and stored at À801C until use. For extraction of protein, an approximate 100-200 mg of frozen tissue was homogenized using a Polytron PT 1200 B in 4 ml of tissue homogenate buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM PMSF; 1 mg/ml aprotinin; 1 mg/ml leupeptin; 1 mM Na 3 VO 4 ; 50 mM NaF and 1 mg/ml pepstatin). Homogenates were incubated overnight at 41C on a vertical rotator, and the extracts were cleared by spinning in an Eppendorf cenrifuge at 20 800 RCF, twice at 41C for 20 min. Supernatant was kept frozen at À201C until use.
Preparation and analyses of cell lysates and protein homogenates for Bcl-2, Bax and cytochrome c levels A measure of 50 mg of cell lysate or 15 mg of protein homogenate lysate (determined by spectrophotometric protein assays) was added to 3 Â SDS-PAGE sample buffer. Samples were heated at 1001C and analysed on a 12% (Bax, Bcl-2) or 15% (cytochrome c) polyacrylamide gel (Bio-Rad; Hercules, CA, USA). Protein was transferred to a Hybond nitrocellulose membrane (Amersham, Arlington Heights, IL, USA) for 2.5 h at 12 W. A high molecular weight rainbow marker (Amersham) was used to confirm the protein size as well as the efficacy of transfer. Following transfer, the membranes were blocked overnight at 41C in TBS containing 5% non-fat powdered milk and 0.05% Tween-20. Membranes were incubated with Bax antiserum (sc-493; Santa Cruz Biotechnology) at a 1 : 1000 dilution. A Bcl-2 monoclonal antibody (AM43; Oncogene Research Products, Boston, MA, USA) was used at a concentration of at 0.2 mg/ml for analysis of murine tissue; a Bcl-2 polyclonal antibody (sc-783; Santa Cruz Biotechnology, CA, USA) was used at a 1 : 1000 dilution for analysis of human breast cancer cells. A cytochrome c monoclonal antibody (sc-13560; Santa Cruz Biotechnology) was used at a 1 : 1000 dilution for analysis of murine tissue; a second cytochrome c monoclonal antibody (7H8.2C12; BD Transduction Laboratories, LA, CA, USA) was used at a 1 : 250 dilution in the analysis of cell lysates. The cytochrome c antibody was incubated overnight at 41C with gentle agitation; all other antibodies were incubated for 1 h at 41C with gentle agitation. Goat anti-mouse (Bcl-2, cytochrome c) or goat antirabbit (Bax) HRP-conjugated secondary antibodies (BioRad, Hercules, CA, USA) were diluted 1 : 2000, and the blots incubated for 2-4 h at room temperature. Bands were visualized using the ECL detection system (Amersham), as per the manufacturer's instructions. To confirm that equivalent amounts of total protein were added to each well, membranes were stripped by incubation in 100 mM bmercaptoethanol/2% SDS/62.5 mM Tris-HCl pH 6.7 at 501C for 30 min, and reprobed with an anti-a-actin monoclonal antibody (Sigma, St Louis, MO, USA) for analysis of the cell lysates, or an anti-b-tubulin monoclonal antibody (Sigma, St Louis, MO, USA) for analysis of the protein homogenates.
Quantitative analysis of Western blotting results
Western blotting images were saved as TIFF-type files and analysed using the BioRad densitometric analysis system Quantity One, following the instructions of the User Guide. After normalization to levels of a-tubulin, the densitometric values of the nontransgenic controls were designated as 100%, and other values were defined as percentages of these controls.
Statistical analyses
All values are given as means7s.e. Statistical analyses were performed using the program StatsDirect version 1.9.8 (CamCode, Cambridge, England) with one-way ANOVA and a Tukey-multiple comparison test. P-values less than 0.01 were considered highly statistically significant and Pvalues between 0.01 and 0.05 were considered statistically significant.
